Clearer brain scans: new agent shows promise for tumor detection
NCT ID NCT06057168
Summary
This completed trial tested whether a new MRI contrast agent called Elucirem could produce clearer images of brain tumors compared to an existing agent called Dotarem. The study involved 138 adults with primary or recurrent brain gliomas who underwent specialized MRI scans. Researchers compared the quality of blood flow maps generated by both agents to see which provided better diagnostic information for tumor assessment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BRAIN TUMOR, RECURRENT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Debreceni Egyetem
Debrecen, Hungary
-
IRCCS C.Mondino, Istituto Neurologico Nazionale, Fondazione
Pavia, Italy
-
Independent Public Teaching Hospital no 1 Department of Interventional Radiology and Diagnostic Imaging
Lublin, Poland
-
Országos Idegtudományi Intézet - Neuroonkológiai és Intracraniá
Budapest, Hungary
-
Ospedale Papa Giovanni XXIII
Bergamo, Italy
-
Ospedale San Raffaele- Neuroradiologia
Milan, Italy
-
Pecsi Tudomanyegyetem Klinikai Kozpont
Pécs, Hungary
-
Policlinico Universitario Agostino Gemelli
Roma, Italy
-
Semmelweis Egyetem - Neurologiai Klinika
Budapest, Hungary
-
Szpital Specjalistyczny im.L.Rydygiera
Krakow, Poland
-
Uniwersyteckie Centrum Kliniczne w Gdansku
Gdansk, Poland
Conditions
Explore the condition pages connected to this study.